ANI Pharmaceuticals, Inc. (ANIP)

ANI Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	35.55	17.15	-49.52	-42.79	-22.55	6.09
Depreciation & Amortization	61.42	61.06	59.65	47.25	44.64	44.61
Share-Based Compensation	23.25	20.65	14.6	10.49	12.94	9.22
Other Operating Activities	-4.41	18.47	-57.56	-11.82	-19.76	-14.29
Operating Cash Flow	115.8	118.96	-31.2	3.32	15.27	45.63
Operating Cash Flow Growth	1163.82%	-	-	-78.24%	-66.54%	-31.97%
Capital Expenditures	2.41	-8.87	-8.13	0.09	-6.14	-6.64
Acquisitions	-9.64	-9.64	-7.61	-105.58	-62.19	-20.91
Investing Cash Flow	-7.23	-18.51	-15.74	-105.48	-68.32	-27.55
Share Issuance / Repurchase	81.89	84.56	-0.5	70.76	-0.91	4.71
Debt Issued / Paid	-3	-3	-3	99.02	-0.53	-3.46
Other Financing Activities	-26.63	-14.13	-1.63	24.81	-	-
Financing Cash Flow	52.26	67.44	-5.13	194.6	-1.44	1.25
Net Cash Flow	160.84	167.89	-52.07	92.43	-54.49	19.33
Free Cash Flow	118.22	110.09	-39.33	3.41	9.13	39
Free Cash Flow Growth	18458.56%	-	-	-62.61%	-76.58%	-36.42%
Free Cash Flow Margin	22.85%	22.61%	-12.43%	1.58%	4.38%	18.88%
Free Cash Flow Per Share	6.09	6.05	-2.42	0.27	0.76	3.24

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).